| Literature DB >> 31620224 |
Juliet A Costoplus1, Karen H Veale1, Qifeng Qiu1, Jose F Ponte1, Leanne Lanieri1, Yulius Setiady1, Ling Dong1, Anna Skaletskaya1, Laura M Bartle1, Paulin Salomon1, Rui Wu1, Erin K Maloney1, Yelena V Kovtun1, Olga Ab1, Kate Lai1, Ravi V J Chari1, Wayne C Widdison1.
Abstract
A new type of antibody-drug conjugate (ADC) has been prepared that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker. Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated. Conjugates were prepared with peptide linkers containing only alanyl residues, which were all l isomers or had a single d residue in one of the three positions. A d-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety. Increasing the number of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity. ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.Entities:
Year: 2019 PMID: 31620224 PMCID: PMC6792174 DOI: 10.1021/acsmedchemlett.9b00310
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345